
QIAGEN N.V. QGEN
QIAGEN N.V. Gross Profit | QGEN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit QIAGEN N.V.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 967 M | 1.23 B | 1.38 B | 1.45 B | 1.23 B | 1.01 B | 1 B | 923 M | 845 M | 826 M | 865 M | 815 M | 824 M | 750 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 B | 750 M | 1.03 B |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Syneos Health
SYNH
|
4.42 B | - | - | $ 4.46 B | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
156 K | - | 5.66 % | $ 22.7 M | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Psychemedics Corporation
PMD
|
7.1 M | - | -1.84 % | $ 15.3 M | ||
|
Quotient Limited
QTNT
|
14.9 M | - | -11.32 % | $ 1.1 M | ||
|
T2 Biosystems
TTOO
|
-3.15 M | - | -39.35 % | $ 313 K | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
Bioventus
BVS
|
388 M | $ 13.0 | 1.39 % | $ 866 M | ||
|
DarioHealth Corp.
DRIO
|
12.7 M | $ 6.75 | 2.31 % | $ 26.9 M | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Accelerate Diagnostics
AXDX
|
2.7 M | - | -61.36 % | $ 2.46 M | ||
|
Anixa Biosciences
ANIX
|
83.8 K | $ 2.69 | 1.45 % | $ 87.3 K | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
Biodesix
BDSX
|
18.5 M | $ 27.7 | 1.09 % | $ 209 M | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.56 | 17.29 % | $ 8.49 M | ||
|
Burning Rock Biotech Limited
BNR
|
403 M | $ 11.68 | 0.69 % | $ 123 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 52.64 | 0.52 % | $ 2.81 B | ||
|
Co-Diagnostics
CODX
|
400 K | $ 1.14 | 2.7 % | $ 1.52 M | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 272.88 | 0.59 % | $ 13.5 B | ||
|
Castle Biosciences
CSTL
|
53 M | $ 35.5 | 6.16 % | $ 1.03 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 247.08 | 3.9 % | $ 27.4 B | ||
|
Meridian Bioscience
VIVO
|
188 M | - | - | $ 1.49 B | ||
|
Biomerica
BMRA
|
362 K | $ 2.3 | 0.42 % | $ 6.7 M | ||
|
Fulgent Genetics
FLGT
|
131 M | $ 21.28 | 3.05 % | $ 655 M | ||
|
Guardant Health
GH
|
144 M | $ 175.65 | 4.65 % | $ 22 B | ||
|
ICON Public Limited Company
ICLR
|
817 M | $ 172.45 | 2.08 % | $ 13.5 B | ||
|
IDEXX Laboratories
IDXX
|
2.66 B | $ 510.73 | 0.23 % | $ 41.1 B | ||
|
Danaher Corporation
DHR
|
14.5 B | $ 209.36 | 3.01 % | $ 149 B | ||
|
Illumina
ILMN
|
2.87 B | $ 222.29 | 6.76 % | $ 34.5 B | ||
|
IQVIA Holdings
IQV
|
3.79 B | $ 269.67 | 1.51 % | $ 46.4 B | ||
|
Brainsway Ltd.
BWAY
|
30.6 M | $ 13.46 | 0.14 % | $ 457 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 323.97 | 2.75 % | $ 27 B | ||
|
Lantheus Holdings
LNTH
|
942 M | $ 100.73 | 0.41 % | $ 6.8 B | ||
|
DexCom
DXCM
|
2.8 B | $ 86.45 | 2.09 % | $ 33.7 B | ||
|
Medpace Holdings
MEDP
|
246 M | $ 620.48 | 4.21 % | $ 17.9 B | ||
|
Mettler-Toledo International
MTD
|
2.39 B | $ 1 330.4 | 3.47 % | $ 27.4 B | ||
|
Myriad Genetics
MYGN
|
577 M | $ 3.88 | 2.37 % | $ 359 M | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 5.66 | 1.13 % | $ 4.45 M | ||
|
NeoGenomics
NEO
|
314 M | $ 18.89 | 2.61 % | $ 2.42 B | ||
|
Neogen Corporation
NEOG
|
408 M | $ 12.25 | 2.51 % | $ 2.66 B | ||
|
National Research Corporation
NRC
|
81.5 M | $ 21.96 | 5.63 % | $ 492 M | ||
|
Natera
NTRA
|
127 M | $ 350.78 | 2.63 % | $ 48 B | ||
|
OPKO Health
OPK
|
206 M | $ 1.57 | 0.64 % | $ 1.18 B | ||
|
Pacific Biosciences of California
PACB
|
45.8 M | $ 1.34 | 0.37 % | $ 402 M | ||
|
Koninklijke Philips N.V.
PHG
|
8.06 B | $ 24.9 | 1.99 % | $ 23.6 B | ||
|
Personalis
PSNL
|
22.1 M | $ 16.1 | 0.31 % | $ 1.44 B |